Von Willebrand factor and coronary heart disease: Prospective study and meta-analysis

European Heart Journal

Volumn 23, Issue 22, 2002, Pages 1764-1770

  Whincup, P H ^a   Danesh, J ^b   Walker, M ^c   Lennon, L ^c   Thomson, A ^c   Appleby, P ^d   Rumley, A ^e   Lowe, G D O ^e  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d RADCLIFFE INFIRMARY   (United Kingdom)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Coagulation; Coronary heart disease; Epidemiology

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; HOMOCYSTEINE; IMMUNOGLOBULIN G ANTIBODY; LIPID; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY RISK; ENZYME IMMUNOASSAY; HEART INFARCTION; HELICOBACTER PYLORI; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERUM; SMOKING; UNITED KINGDOM; VASCULAR ENDOTHELIUM;

EID: 0036847634     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3237     Document Type: Article

References (44)

1. Mannucci PM. Von Willebrand factor: A marker of endothelial damage? Arterioscler Thromb Vasc Biol 1998; 18: 1359-62.
2. Lowe GDO. Haemostatic risk factors for arterial and venous thrombosis. In: Poller L, Ludlam CA, eds. Recent Advances in Blood Coagulation. Edinburgh: Churchill Livingstone, 1997: 69-96.
3. Fosang AJ, Smith PJ. To clot or not. Nature 2001; 413: 475-6.
4. Folsom AR, Wu K, Rosamond WD, Sharret AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
5. Smith FB, Lee AJ, Fowkes FGR, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
6. Rumley A, Lowe GDO, Sweetnam PM, Yarnell JWG, Ford RP. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol 1999; 105: 110-16.
7. Thogersen AM, Jannson J-H, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-7.
8. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994; 88: 601-7.
9. Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG. British Regional Heart Study: Cardiovascular risk factors in middle-aged men in 24 towns. BMJ 1981; 283: 179-86.
10. Walker M, Shaper AG, Lennon L, Whincup PH. Twenty year follow-up of a cohort based in general practice in 24 British towns. J Publ Health Med 2000; 22: 479-85.
11. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Circulation 1994; 90: 583-612.
12. Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M. Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle-aged men. Heart 1996; 75: 568-72.
13. Whincup PH, Danesh J, Walker M et al. Prospective study of virulent strains of Helicobacter pylori and coronary heart disease in late middle-aged men. Circulation 2000; 101: 1647-52.
14. Yarnell JW, Sweetnam PM, Rumley A, Lowe GD. Lifestyle and hemostatic risk factors for ischemic heart disease: The Caerphilly Study. Arterioscler Thromb Vasc Biol 2000; 20: 271-9.
15. Wong Y-K, Sueur JM, Fall CHD, Orfila J, Ward ME. The species specificity of the micro-immunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring antibodies against Chlamydia pneumoniae. J Clin Pathol 1999; 2: 99-103.
16. Danesh J, Muir J, Wong Y-K, Ward M, Gallimore R, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins: Population-based study. Eur Heart J 1999; 20: 954-9.
17. Refsum H, Ueland PM, Svardal AM. Fully automated fluorescence assay for determining total homocysteine in plasma. Clin Chem 1989: 35: 1921-7.
18. Parving H-H. Concentrations of von Willebrand Factor in diabetes. BMJ 1996; 312: 642.
19. Danesh J, Whincup PH, Walker M et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
20. Clarke R, Shipley M, Lewington S et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999; 150: 341-53.
21. Danesh J, Collins R, Appleby P, Peto R, Fibrinogen, C-reactive protein, albumin or white cell count: Meta-analyses of prospective studies of coronary heart disease. JAMA 1998; 279: 1477-82.
22. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000; 133: 81-91.
23. Smith FB, Rumley A, Lee AJ, Leng GC, Fowkes FGR, Lowe GDO. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998; 100: 758-63.
24. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
25. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) Study. Arterioscler Thromb Vasc Biol 2000; 20: 2019-23.
26. Moss AJ, Goldstein RE, Marder VJ et al. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99: 2517-22.
27. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow-up of survivors of acute myocardial infarction. Heart 1998; 80: 334-7.
28. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-5.
29. Hamsten A, Walldius G, Szamosi A et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
30. Jager A, van Hinsbergh VWM, Kostense PJ et al. Von Willebrand factor, C-reactive protein and 5-year mortality in diabetic and nondiabetic subjects. Arterioscler Thromb Vasc Biol 1999; 19: 3078.
31. Standl E, Dahl B, Weichenhain B, Stiegler H, Hormann A, Holle R. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: The Munich General Practitioner Project. Diabetologia 1996; 39: 1540-5.
32. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, den Ottolander GJH. Urinary albumin excretion, cardiovascular disease and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-23.
33. Blann AD, Miller JP, McCollum CN. Von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. Atherosclerosis 1997; 132: 151-6.
34. Blann AD, McCollum CN. Von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinolysis 1999; 10: 375-81.
35. Agewall S, Wikstrand J, Fagerberg B. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men. J Hypertens 1998; 16: 537-41.
36. Kalaria VG, Zareba W, Moss AJ et al. Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patient after acute myocardial infarction. The THROMBO investigators. Am J Cardiol 2000; 85: 1401-8.
37. Pottinger BE, Read RC, Paleolog EM, Pearson JD. Von Willebrand factor is an acute phase protein in man. Thromb Res 1989; 53: 389-95.
38. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: Does it exist? Br J Haematol 1995; 90: 234-41.
39. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet 1997; 350: 430-6.
40. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: Systematic review of published epidemiological studies. J Cardiovasc Risk 1998; 5: 229-32.
41. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999; 340: 115-21.
42. Danesh J, Youngman L, Clark S, Parish S, Peto R, Collins R. Helicobacter pylori infection and early onset myocardial infarction: Case-control and sibling pairs study. BMJ 1999; 319: 1157-62.
43. McColl K, Murray L, El-Omar E et al. Symptomatic benefit from eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. N Engl J Med 1998; 339: 1869-74.
44. Pernerstorfer T, Eichler H-G, Stohlawetz P, Speiser W, Jilma B. Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand factor levels in healthy men. Atherosclerosis 2001; 155: 389-93.